Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Avecho Biotechnology Limited ( (AU:AVE) ) has provided an update.
Avecho Biotechnology has reported a change in the indirect holdings of director Gregory Collier, primarily through his interests in Beacon Super Fund Pty Ltd and Barwon Biotechnology Pty Ltd. The disclosure details the restructuring of his exposure to Avecho securities, including the exercise and expiry of various options.
Collier exercised 800,000 quoted options at $0.012 each, resulting in the issue of an equivalent number of fully paid ordinary shares, while 10,949,999 quoted options expired unexercised. Following these transactions, his indirect interests now comprise increased ordinary shareholdings and a remaining tranche of long-dated unquoted options, clarifying his ongoing equity alignment with the company and providing transparency to investors about director ownership changes.
More about Avecho Biotechnology Limited
Avecho Biotechnology Limited is an Australian biotechnology company listed on the ASX, focused on developing and commercialising pharmaceutical and related products. The company leverages specialised delivery technologies to enhance the effectiveness of its formulations and targets both domestic and international healthcare markets.
Average Trading Volume: 9,582,143
Technical Sentiment Signal: Sell
Current Market Cap: A$44.17M
Learn more about AVE stock on TipRanks’ Stock Analysis page.